CD274 and cancer: The majority of currently available ICIs work at this seventh step by blocking the PD-1/PD-L1 pathway, which usually acts as an ‘immunostat’ to prevent auto-immunity [5] but can also be up-regulated in patients with cancer [6], thereby removing the negative immune regulation on CTLs and reinstating the anti-cancer response.